CD274 and neoplasm: Anti-PD-1 antibodies (pembrolizumab, nivolumab) and anti-PD-L1 antibodies (atezolizumab, avelumab, durvalumab) disrupt this interaction, reinvigorating T cell function and anti-tumor immunity [13].